Company: JUNS
Filing Date: 2025-11-06
Form Type: DEF 14A
Source: 0001493152-25-020988
Chunk: 62

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-06
Form: DEF 14A
Chunk 62
---
 Shares at the time of grant (or, in the case of an “incentive stock option” granted to a 10% or more stockholder of our company, or subsidiary, as applicable, 110% of the fair market value). Options granted under the 2025 Plan in substitution or exchange for options or awards of another company involved in a corporate transaction with us or a subsidiary will have an exercise price that is intended to preserve the economic value of the award that is replaced. The fair market value of our Shares generally means the closing price of our Shares on the option grant date. The exercise price of any stock options granted under the 2025 Plan will be paid by check, by tendering previously acquired Shares having a fair market value at the time of the exercise equal to the exercise price, by a cashless broker-assisted exercise that complies with law, by withholding of Shares otherwise deliverable to the option holder upon exercise of the option or any other method approved or accepted by our Compensation Committee in its discretion. Our Compensation Committee will determine whether any fractional Shares will be settled in cash or forfeited.

| -36- |

Options will become exercisable and expire at the times and on the terms established by our Compensation Committee, not later than the tenth anniversary of the grant date. If the exercise of a “nonqualified stock option” on its scheduled expiration date would violate law, the option may be extended until its exercise would not violate law. Options generally terminate when the holder’s employment or service with us terminates. However, an option may be exercised for up to one year following the holder’s termination of employment or services in specified circumstances, unless our Compensation Committee or the option agreement permits exercise of the option following the holder’s termination to any greater or lesser extent.

Stock Appreciation Rights

Stock appreciation rights, or SARs, may be granted by our Compensation Committee (either in connection with, or independent of, an option) upon such terms and conditions determined by our Compensation Committee which are permitted under the 2025 Plan. Generally, SARs are awards that, upon their exercise, give the holder a right to receive from us an amount equal to the product of (1) the number of Shares for which the SAR is exercised, multiplied by (2) the excess of the (a) fair market value of a Share on the exercise date, over (b) the grant price per Share. The grant price per share cannot be less than 100% of the fair market value of a Share on the grant date of